341 related articles for article (PubMed ID: 35409171)
1. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
Mahdi M; Hermán L; Réthelyi JM; Bálint BL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409171
[TBL] [Abstract][Full Text] [Related]
2. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Hoertel N
JAMA Netw Open; 2021 Nov; 4(11):e2136510. PubMed ID: 34779851
[No Abstract] [Full Text] [Related]
3. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Oskotsky T; Maric I; Tang A; Oskotsky B; Wong RJ; Aghaeepour N; Sirota M; Stevenson DK
JAMA Netw Open; 2021 Nov; 4(11):e2133090. PubMed ID: 34779847
[TBL] [Abstract][Full Text] [Related]
4. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Nakhaee H; Zangiabadian M; Bayati R; Rahmanian M; Ghaffari Jolfayi A; Rakhshanderou S
PLoS One; 2022; 17(10):e0267423. PubMed ID: 36201406
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.
Bonnet U; Juckel G
J Clin Psychopharmacol; 2022 May-Jun 01; 42(3):284-292. PubMed ID: 35420565
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.
Foletto VS; da Rosa TF; Serafin MB; Hörner R
Eur J Clin Pharmacol; 2022 Oct; 78(10):1601-1611. PubMed ID: 35943535
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of fluvoxamine for COVID-19: a historical review.
Hashimoto Y; Suzuki T; Hashimoto K
Mol Psychiatry; 2022 Apr; 27(4):1898-1907. PubMed ID: 34997196
[TBL] [Abstract][Full Text] [Related]
8. [Selective serotonin reuptake inhibitors--current knowledge].
Dudek D; Zieba A; Siwek M; Wróbel A
Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
10. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Finley PR
Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
[TBL] [Abstract][Full Text] [Related]
13. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
Schloer S; Brunotte L; Goretzko J; Mecate-Zambrano A; Korthals N; Gerke V; Ludwig S; Rescher U
Emerg Microbes Infect; 2020 Dec; 9(1):2245-2255. PubMed ID: 32975484
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Deng J; Rayner D; Ramaraju HB; Abbas U; Garcia C; Heybati K; Zhou F; Huang E; Park YJ; Moskalyk M
Clin Microbiol Infect; 2023 May; 29(5):578-586. PubMed ID: 36657488
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Pashaei Y
J Clin Neurosci; 2021 Jun; 88():163-172. PubMed ID: 33992179
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluoxetine hydrochloride and fluvoxamine maleate on different preparations of isolated guinea pig and rat organ tissues.
Velasco A; Alamo C; Hervás J; Carvajal A
Gen Pharmacol; 1997 Apr; 28(4):509-12. PubMed ID: 9147017
[TBL] [Abstract][Full Text] [Related]
17. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship.
Hashimoto K
Cent Nerv Syst Agents Med Chem; 2009 Sep; 9(3):197-204. PubMed ID: 20021354
[TBL] [Abstract][Full Text] [Related]
18. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.
Caccia S
Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day.
Eugene AR
F1000Res; 2021; 10():477. PubMed ID: 36262792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
